12/3
04:28 pm
cv
CapsoVision (NASDAQ:CV) had its "sell (e)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
CapsoVision (NASDAQ:CV) had its "sell (e)" rating reaffirmed by analysts at
Weiss Ratings.
11/27
02:45 pm
cv
CapsoVision (NASDAQ:CV) had its "sell (e)" rating reaffirmed by analysts at
Weiss Ratings.
Neutral
Report
CapsoVision (NASDAQ:CV) had its "sell (e)" rating reaffirmed by analysts at
Weiss Ratings.
11/21
01:56 pm
cv
CapsoVision (NASDAQ:CV) had its "sell (e)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
CapsoVision (NASDAQ:CV) had its "sell (e)" rating reaffirmed by analysts at
Weiss Ratings.
11/20
04:11 pm
cv
CapsoVision to Participate in the Benchmark 14th Annual Discovery Investor Conference [Yahoo! Finance]
Low
Report
CapsoVision to Participate in the Benchmark 14th Annual Discovery Investor Conference [Yahoo! Finance]
11/20
04:05 pm
cv
CapsoVision to Participate in the Benchmark 14th Annual Discovery Investor Conference
Low
Report
CapsoVision to Participate in the Benchmark 14th Annual Discovery Investor Conference
11/14
12:15 pm
cv
CapsoVision (NASDAQ:CV) had its "speculative buy" rating reaffirmed by analysts at Benchmark Co..
Low
Report
CapsoVision (NASDAQ:CV) had its "speculative buy" rating reaffirmed by analysts at Benchmark Co..
11/12
08:37 am
cv
CapsoVision Inc (CV) Q3 2025 Earnings Report Preview: What to Expect [Yahoo! Finance]
Low
Report
CapsoVision Inc (CV) Q3 2025 Earnings Report Preview: What to Expect [Yahoo! Finance]
11/10
04:41 pm
cv
CapsoVision Submits Breakthrough Device Designation Application to FDA for Pancreatic Cancer Screening Capsule [Yahoo! Finance]
Medium
Report
CapsoVision Submits Breakthrough Device Designation Application to FDA for Pancreatic Cancer Screening Capsule [Yahoo! Finance]
11/10
04:05 pm
cv
CapsoVision Submits Breakthrough Device Designation Application to FDA for Pancreatic Cancer Screening Capsule
Medium
Report
CapsoVision Submits Breakthrough Device Designation Application to FDA for Pancreatic Cancer Screening Capsule
11/7
06:19 am
cv
CapsoVision (NASDAQ:CV) was upgraded by analysts at Zacks Research to a "hold" rating.
Low
Report
CapsoVision (NASDAQ:CV) was upgraded by analysts at Zacks Research to a "hold" rating.
11/5
07:31 am
cv
CapsoVision (NASDAQ:CV) was upgraded by analysts at Roth Capital to a "strong-buy" rating.
Medium
Report
CapsoVision (NASDAQ:CV) was upgraded by analysts at Roth Capital to a "strong-buy" rating.
11/4
07:01 am
cv
CapsoVision (NASDAQ:CV) was given a new $7.00 price target on by analysts at Roth Capital.
Medium
Report
CapsoVision (NASDAQ:CV) was given a new $7.00 price target on by analysts at Roth Capital.
11/3
08:00 am
cv
CapsoVision Appoints David Garcia as Senior Vice President of Finance
Medium
Report
CapsoVision Appoints David Garcia as Senior Vice President of Finance
10/30
04:05 pm
cv
CapsoVision to Release Third Quarter 2025 Financial Results on Thursday, November 13, 2025
Medium
Report
CapsoVision to Release Third Quarter 2025 Financial Results on Thursday, November 13, 2025
9/25
04:05 pm
cv
CapsoVision to Participate in the 4th Annual ROTH Healthcare Opportunities Conference
Low
Report
CapsoVision to Participate in the 4th Annual ROTH Healthcare Opportunities Conference